Published in PLoS One on May 20, 2010
ALDH1A isozymes are markers of human melanoma stem cells and potential therapeutic targets. Stem Cells (2012) 1.70
High-throughput chemical screens identify disulfiram as an inhibitor of human glioblastoma stem cells. Oncotarget (2012) 1.34
Aldehyde dehydrogenase 1A1 in stem cells and cancer. Oncotarget (2016) 1.06
Identification of CBX3 and ABCA5 as putative biomarkers for tumor stem cells in osteosarcoma. PLoS One (2012) 0.96
Cisplatin-resistant cells in malignant pleural mesothelioma cell lines show ALDH(high)CD44(+) phenotype and sphere-forming capacity. BMC Cancer (2014) 0.94
Melanoma stem cells and metastasis: mimicking hematopoietic cell trafficking? Lab Invest (2013) 0.92
Secretome from senescent melanoma engages the STAT3 pathway to favor reprogramming of naive melanoma towards a tumor-initiating cell phenotype. Oncotarget (2013) 0.92
Multiple pluripotent stem cell markers in human anaplastic thyroid cancer: the putative upstream role of SOX2. Thyroid (2013) 0.92
Susceptibility to cytotoxic T cell lysis of cancer stem cells derived from cervical and head and neck tumor cell lines. J Cancer Res Clin Oncol (2012) 0.91
Thoughts about cancer stem cells in solid tumors. World J Stem Cells (2012) 0.85
Mek inhibition results in marked antitumor activity against metastatic melanoma patient-derived melanospheres and in melanosphere-generated xenografts. J Exp Clin Cancer Res (2013) 0.82
Isolation of human melanoma stem cells using ALDH as a marker. Curr Protoc Stem Cell Biol (2013) 0.81
Hypoxia-shaped vascular niche for cancer stem cells. Contemp Oncol (Pozn) (2015) 0.81
Cancer stem cells in breast cancer. Cancers (Basel) (2011) 0.80
Loss of ALDH1A1 expression is an early event in the pathogenesis of ovarian high-grade serous carcinoma. Mod Pathol (2014) 0.79
An Endogenous Electron Spin Resonance (ESR) signal discriminates nevi from melanomas in human specimens: a step forward in its diagnostic application. PLoS One (2012) 0.79
Verification of ALDH Activity as a Biomarker in Colon Cancer Stem Cells-Derived HT-29 Cell Line. Iran J Cancer Prev (2015) 0.79
Identification of biological properties of intralymphatic tumor related to the development of lymph node metastasis in lung adenocarcinoma. PLoS One (2013) 0.78
Distinct Small RNA Signatures in Extracellular Vesicles Derived from Breast Cancer Cell Lines. PLoS One (2016) 0.75
Aldehyde dehydrogenase isozymes: markers of cancer stem cells in human melanoma. Expert Rev Dermatol (2016) 0.75
Aldehyde dehydrogenases in cancer stem cells: potential as therapeutic targets. Ann Transl Med (2016) 0.75
High ALDH1 expression correlates with better prognosis in tumorigenic malignant melanoma. Mod Pathol (2017) 0.75
Iterative sorting reveals CD133+ and CD133- melanoma cells as phenotypically distinct populations. BMC Cancer (2016) 0.75
Aldehyde dehydrogenase activity plays a Key role in the aggressive phenotype of neuroblastoma. BMC Cancer (2016) 0.75
ALDH1A3 is epigenetically regulated during melanocyte transformation and is a target for melanoma treatment. Oncogene (2017) 0.75
Stem cells, cancer, and cancer stem cells. Nature (2001) 50.27
ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell (2007) 22.89
Efficient tumour formation by single human melanoma cells. Nature (2008) 16.35
Melanoma biology and new targeted therapy. Nature (2007) 10.71
Identification of cells initiating human melanomas. Nature (2008) 8.28
Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res (2009) 7.98
A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res (2005) 7.86
Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer. Mol Cancer Res (2009) 4.36
Malignant melanoma: genetics and therapeutics in the genomic era. Genes Dev (2006) 4.24
Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy. PLoS One (2008) 3.97
Inhibition of aldehyde dehydrogenase and retinoid signaling induces the expansion of human hematopoietic stem cells. Proc Natl Acad Sci U S A (2006) 3.73
Current systemic therapy for metastatic melanoma. Expert Rev Anticancer Ther (2009) 3.65
Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers. Clin Cancer Res (2009) 3.28
Characterization of cells with a high aldehyde dehydrogenase activity from cord blood and acute myeloid leukemia samples. Stem Cells (2005) 3.00
ALDH1 as a functional marker of cancer stem and progenitor cells. Stem Cells Dev (2010) 2.07
Stem cell marker aldehyde dehydrogenase 1-positive breast cancers are characterized by negative estrogen receptor, positive human epidermal growth factor receptor type 2, and high Ki67 expression. Cancer Sci (2009) 1.79
ALDH1 expression correlates with favorable prognosis in ovarian cancers. Mod Pathol (2009) 1.70
Human aldehyde dehydrogenases: potential pathological, pharmacological, and toxicological impact. J Biochem Mol Toxicol (2003) 1.64
Characterization of melanoma cells capable of propagating tumors from a single cell. Cancer Res (2010) 1.50
Production and characterization of monoclonal antibody to a melanoma specific glycoprotein. Hybridoma (1981) 1.42
Extended passaging, but not aldehyde dehydrogenase activity, increases the chondrogenic potential of human adipose-derived adult stem cells. J Cell Physiol (2006) 1.42
Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors. Ann Oncol (2009) 1.33
Melanoma proteoglycan modifies gene expression to stimulate tumor cell motility, growth, and epithelial-to-mesenchymal transition. Cancer Res (2009) 1.03
Human malignant melanoma harbours a large fraction of highly clonogenic cells that do not express markers associated with cancer stem cells. Pigment Cell Melanoma Res (2010) 0.91
S100A4 and metastasis: a small actor playing many roles. Am J Pathol (2009) 2.80
Helper-dependent adenovirus vectors elicit intact innate but attenuated adaptive host immune responses in vivo. J Virol (2004) 1.70
Expression of S100A4 by a variety of cell types present in the tumor microenvironment of human breast cancer. Int J Cancer (2007) 1.53
Distinct choline metabolic profiles are associated with differences in gene expression for basal-like and luminal-like breast cancer xenograft models. BMC Cancer (2010) 1.46
DNA methylation profiling of ovarian carcinomas and their in vitro models identifies HOXA9, HOXB5, SCGB3A1, and CRABP1 as novel targets. Mol Cancer (2007) 1.44
Photochemically mediated delivery of AdhCMV-TRAIL augments the TRAIL-induced apoptosis in colorectal cancer cell lines. Cancer Biol Ther (2006) 1.42
Oct3/4 and Sox2 are significantly associated with an unfavorable clinical outcome in human esophageal squamous cell carcinoma. Anticancer Res (2009) 1.41
Expression of Ephb2 and Ephb4 in breast carcinoma. Pathol Oncol Res (2004) 1.41
Molecular profiling and characterization of luminal-like and basal-like in vivo breast cancer xenograft models. Mol Oncol (2009) 1.37
Matrix metalloproteinases participate in osteosarcoma invasion. J Surg Res (2005) 1.32
Twelve colorectal cancer cell lines exhibit highly variable growth and metastatic capacities in an orthotopic model in nude mice. Eur J Cancer (2004) 1.28
Nuclear localization of the metastasis-related protein S100A4 correlates with tumour stage in colorectal cancer. J Pathol (2003) 1.23
Identification and characterization of cells with cancer stem cell properties in human primary lung cancer cell lines. PLoS One (2013) 1.17
Photochemical internalisation in drug and gene delivery. Adv Drug Deliv Rev (2004) 1.15
Expression of HIWI in human esophageal squamous cell carcinoma is significantly associated with poorer prognosis. BMC Cancer (2009) 1.13
The clinical significance of EphA2 and Ephrin A-1 in epithelial ovarian carcinomas. Gynecol Oncol (2005) 1.09
The hypoxic microenvironment upgrades stem-like properties of ovarian cancer cells. BMC Cancer (2012) 1.09
The prognostic impact of EphB2/B4 expression on patients with advanced ovarian carcinoma. Gynecol Oncol (2006) 1.09
PI3K-AKT-mTOR pathway is dominant over androgen receptor signaling in prostate cancer cells. Cell Oncol (2010) 1.06
Immunofluorometric assay for the metastasis-related protein S100A4: release of S100A4 from normal blood cells prohibits the use of S100A4 as a tumor marker in plasma and serum. Tumour Biol (2004) 1.05
Prostate cancer cell lines under hypoxia exhibit greater stem-like properties. PLoS One (2011) 1.05
Activation of NF-kappaB by extracellular S100A4: analysis of signal transduction mechanisms and identification of target genes. Int J Cancer (2008) 1.05
Prognostic value of EphA2 and EphrinA-1 in squamous cell cervical carcinoma. Gynecol Oncol (2004) 1.03
B7-H3 silencing increases paclitaxel sensitivity by abrogating Jak2/Stat3 phosphorylation. Mol Cancer Ther (2011) 1.03
Amplification and overexpression of COPS3 in osteosarcomas potentially target TP53 for proteasome-mediated degradation. Oncogene (2003) 1.02
Identification of cancer stem-like side population cells in ovarian cancer cell line OVCAR-3. Ultrastruct Pathol (2009) 0.99
The prognostic value of 14-3-3 isoforms in vulvar squamous cell carcinoma cases: 14-3-3β and ε are independent prognostic factors for these tumors. PLoS One (2011) 0.99
Expression of activated extracellular signal-regulated kinases 1/2 in malignant melanomas: relationship with clinical outcome. Clin Cancer Res (2003) 0.98
Expression of S100A4 combined with reduced E-cadherin expression predicts patient outcome in malignant melanoma. Mod Pathol (2004) 0.98
S100A4 regulates membrane induced activation of matrix metalloproteinase-2 in osteosarcoma cells. Clin Exp Metastasis (2003) 0.98
Combined treatment with Ad-hTRAIL and DTIC or SAHA is associated with increased mitochondrial-mediated apoptosis in human melanoma cell lines. J Gene Med (2007) 0.97
Cystatin E/M suppresses legumain activity and invasion of human melanoma. BMC Cancer (2010) 0.97
FAP-alpha and uPA show different expression patterns in premalignant and malignant esophageal lesions. Ultrastruct Pathol (2008) 0.97
Positional cloning identifies a novel cyclophilin as a candidate amplified oncogene in 1q21. Oncogene (2002) 0.95
The clinicopathological and prognostic impact of 14-3-3 sigma expression on vulvar squamous cell carcinomas. BMC Cancer (2008) 0.95
Metabolic biomarkers for response to PI3K inhibition in basal-like breast cancer. Breast Cancer Res (2013) 0.95
Nuclear legumain activity in colorectal cancer. PLoS One (2013) 0.95
Overexpression of CDC25B, CDC25C and phospho-CDC25C (Ser216) in vulvar squamous cell carcinomas are associated with malignant features and aggressive cancer phenotypes. BMC Cancer (2010) 0.94
The mitogen-activated protein kinase phosphatase vaccinia H1-related protein inhibits apoptosis in prostate cancer cells and is overexpressed in prostate cancer. Cancer Res (2008) 0.94
Signal transduction mechanisms involved in S100A4-induced activation of the transcription factor NF-kappaB. BMC Cancer (2010) 0.93
Subcellular localization pattern of protoporphyrin IX is an important determinant for its photodynamic efficiency of human carcinoma and normal cell lines. J Photochem Photobiol B (2006) 0.93
Biological effects induced by insulin-like growth factor binding protein 3 (IGFBP-3) in malignant melanoma. Int J Cancer (2010) 0.93
STAMP1 is both a proliferative and an antiapoptotic factor in prostate cancer. Cancer Res (2010) 0.93
Predictive value of EphA2 and EphrinA-1 expression in oesophageal squamous cell carcinoma. Anticancer Res (2005) 0.92
Photochemical internalization: a new tool for drug delivery. Curr Pharm Biotechnol (2007) 0.91
Human malignant melanoma harbours a large fraction of highly clonogenic cells that do not express markers associated with cancer stem cells. Pigment Cell Melanoma Res (2010) 0.91
Interplay of choline metabolites and genes in patient-derived breast cancer xenografts. Breast Cancer Res (2014) 0.91
Cytologic screening for esophageal cancer in a high-risk population in Anyang County, China. Acta Cytol (2002) 0.90
In vivo MRI and histopathological assessment of tumor microenvironment in luminal-like and basal-like breast cancer xenografts. J Magn Reson Imaging (2011) 0.90
Specific isolation of disseminated cancer cells: a new method permitting sensitive detection of target molecules of diagnostic and therapeutic value. Clin Exp Metastasis (2007) 0.90
A novel human recombinant single-chain antibody targeting CD166/ALCAM inhibits cancer cell invasion in vitro and in vivo tumour growth. Cancer Immunol Immunother (2010) 0.90
Molecular circuit involving KLK4 integrates androgen and mTOR signaling in prostate cancer. Proc Natl Acad Sci U S A (2013) 0.89
Preclinical dynamic 18F-FDG PET - tumor characterization and radiotherapy response assessment by kinetic compartment analysis. Acta Oncol (2010) 0.88
Proteomic characterization of breast cancer xenografts identifies early and late bevacizumab-induced responses and predicts effective drug combinations. Clin Cancer Res (2013) 0.88
Induction of hypoxia-inducible factor-1alpha overexpression by cobalt chloride enhances cellular resistance to photodynamic therapy. Cancer Lett (2006) 0.88
Safety of neonatal cleft lip repair. J Plast Surg Hand Surg (2010) 0.88
Activation of EDTA-resistant gelatinases in malignant human tumors. Cancer Res (2006) 0.88
Synergistic effect of SCF and G-CSF on stem-like properties in prostate cancer cell lines. Tumour Biol (2012) 0.88
Expression of TIP30 tumor suppressor gene is down-regulated in human colorectal carcinoma. Dig Dis Sci (2009) 0.88
Intermittent and continuous imatinib in a human GIST xenograft model carrying KIT exon 17 resistance mutation D816H. Acta Oncol (2013) 0.86
Notch1 is a 5-fluorouracil resistant and poor survival marker in human esophagus squamous cell carcinomas. PLoS One (2013) 0.85
Human osteosarcoma xenografts and their sensitivity to chemotherapy. Pathol Oncol Res (2004) 0.85
Effect of antiangiogenic therapy on tumor growth, vasculature and kinase activity in basal- and luminal-like breast cancer xenografts. Mol Oncol (2012) 0.84
Altered characteristics of cancer stem/initiating cells in a breast cancer cell line treated with persistent 5-FU chemotherapy. Exp Ther Med (2011) 0.83
Radiosensitization by the histone deacetylase inhibitor vorinostat under hypoxia and with capecitabine in experimental colorectal carcinoma. Radiat Oncol (2012) 0.83
Prognostic significance of dysadherin expression in cervical squamous cell carcinoma. Pathol Oncol Res (2004) 0.83
Targeting inhibitor of apoptosis proteins in combination with dacarbazine or TRAIL in melanoma cells. Cancer Biol Ther (2011) 0.83
Exploring the peritoneal surface malignancy phenotype--a pilot immunohistochemical study of human pseudomyxoma peritonei and derived animal models. Hum Pathol (2010) 0.83
Expression of activated TrkA protein in melanocytic tumors: relationship to cell proliferation and clinical outcome. Am J Clin Pathol (2004) 0.82
In vitro and in vivo properties of CD133 expressing cells from human lung cancer cell lines. Exp Hematol Oncol (2013) 0.82
Melanoma-specific expression in first-generation adenoviral vectors in vitro and in vivo -- use of the human tyrosinase promoter with human enhancers. Cancer Gene Ther (2005) 0.82
CD117 expression in operable oesophageal squamous cell carcinomas predicts worse clinical outcome. Histopathology (2013) 0.81
Expressions of EphA2 and EphrinA-1 in early squamous cell cervical carcinomas and their relation to prognosis. Int J Med Sci (2008) 0.81
5'-CpG island methylation of the FHIT gene is associated with reduced protein expression and higher clinical stage in cervical carcinomas. Ultrastruct Pathol (2003) 0.81
SHBG is an important factor in stemness induction of cells by DHT in vitro and associated with poor clinical features of prostate carcinomas. PLoS One (2013) 0.80
Antitumour activity of oral E7080, a novel inhibitor of multiple tyrosine kinases, in human sarcoma xenografts. Int J Cancer (2011) 0.80
In vivo ³¹P magnetic resonance spectroscopic imaging (MRSI) for metabolic profiling of human breast cancer xenografts. J Magn Reson Imaging (2014) 0.79
Clinical and cell line specific expression profiles of a human gene identified in experimental central nervous system metastases. Anticancer Res (2002) 0.79
VP-16 resistance in the NCI-H460 human lung cancer cell line is significantly associated with glucose-regulated protein78 (GRP78) induction. Anticancer Res (2007) 0.79
The EPH receptor Bs (EPHBs) promoters are unmethylated in colon and ovarian cancers. Epigenetics (2007) 0.79
Lamin A/C cleavage by caspase-6 activation is crucial for apoptotic induction by photodynamic therapy with hexaminolevulinate in human B-cell lymphoma cells. Cancer Lett (2013) 0.78
[Quantity and distribution of CD44+/CD24- cells in breast cancer tissue and the cell lines]. Zhonghua Bing Li Xue Za Zhi (2009) 0.78
Radiosynthesis and biodistribution of a prosthetic group (¹⁸F-FENMA) conjugated to cyclic RGD peptides. Bioconjug Chem (2010) 0.78
CD44(+)/CD24(-) cells are transit progenitors and do not determine the molecular subtypes and clinical parameters in breast carcinomas. Ultrastruct Pathol (2011) 0.78
Photochemically enhanced transduction of polymer-complexed adenovirus targeted to the epidermal growth factor receptor. J Gene Med (2006) 0.78
Impact of hyperthermia on pharmacokinetics of intraperitoneal mitomycin C in rats investigated by microdialysis. J Surg Oncol (2013) 0.78
Chromosome 2q24.2 is lost in sporadic but not in BRCA1-associated ovarian carcinomas. Pathology (2006) 0.77
Colchicine induces membrane-associated activation of matrix metalloproteinase-2 in osteosarcoma cells in an S100A4-independent manner. Biochem Pharmacol (2003) 0.77
Aldehyde dehydrogenase-1 predicts favorable prognosis in patients with vulvar squamous cell carcinoma. Anticancer Res (2014) 0.77
Down-regulation of the apoptosis-inducing factor or Bcl-2 inhibitor of transcription by RNA interference can alleviate TAp63gamma-induced apoptosis in esophageal squamous carcinoma EC9706 cells. Int J Oncol (2009) 0.77
Interferon-gamma-induced suppression of S100A4 transcription is mediated by the class II transactivator. Tumour Biol (2006) 0.77